StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.0
  1. Startseite
  2. /Verbindung

Gatifloxacin

HCID 5379
Neue NotizNeue ReaktionAnfrage stellen
Druckvorschau
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
112811-59-3
Standard-SMILES
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
InChIKey
XUBOMFCQGDBHNK-UHFFFAOYSA-N
Summenformel
C19H22FN3O4
Durchschnittliche Molmasse
375,4 g/mol
Monoisotopische Masse
375,1594344

Überblick

Gatifloxacin is a monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes. It has a role as an antimicrobial agent, an antiinfective agent and an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor. It is a quinolone, a quinolinemonocarboxylic acid, an organofluorine compound, a N-arylpiperazine and a quinolone antibiotic.

Namen und Bezeichner

Bevorzugter Name
Gatifloxacin
IUPAC
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Englischer Name
Gatifloxacin
Summenformel
C19H22FN3O4
Molmasse
375.39

Namen und Synonyme

Gatifloxacin112811-59-3TequinGatifloZymarAM-1155GatifloxacineZymaxidZymergatifloxacin anhydrousAM 11553-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-
Weitere Namen anzeigen
CG5501S)-AHPCGatiquinPD135432PD 135432PD-135432)BMS-206584GASTRODINUM
gatifloxacinoDTXSID50457041-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acidgatifloxacinumPD-1354321-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acidNSC-758701CHEBI:5280

Datenbank-Bezeichner

CAS
112811-59-3
PubChem CID
5379
DTXSID
DTXSID5045704
ChEMBL
CHEMBL31

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-0,7
Polarare Oberfläche (TPSA)
82,1 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
4
Schwere Atome
27
Formalladung
0
Komplexität
653

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic use

LogP2.6
Solubility6.31e-01 g/L
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antibacterial Agents; Quinolones; Fluoroquinolones

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 Einträge

182-185 °C

182 - 185 °C

Physical DescriptionSolid
Dissociation Constants · 4 Einträge

8.74

6

6

9.4

Collision Cross Section · 2 Einträge

189.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

189.03 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (97.5%)

Toxikologische Informationen

Treatment · 1 Eintrag

In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained. (L1712)

Health EffectsAntibiotic resistance
Exposure RoutesOphthalmic. Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%
Toxicity SummaryThe bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
Signs and SymptomsThe most common side effects from antibiotics are diarrhea, nausea, vomiting. Fungal infections of the mouth, digestive tract and vagina can also occur with antibiotics

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

S - Sensory organs

J - Antiinfectives for systemic use

QS - Sensory organs

QJ - Antiinfectives for systemic use

Protein Binding20%
Pharmacodynamics · 1 Eintrag

Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration. is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gatifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Mechanism of ActionThe bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
Biological Half-Life7-14 hours
Metabolism/Metabolites · 2 Einträge

Gatifloxacin undergoes limited biotransformation in humans with less than 1% of the dose excreted in the urine as ethylenediamine and methylethylenediamine metabolites

Gatifloxacin undergoes limited biotransformation in humans with less than 1% of the dose excreted in the urine as ethylenediamine and methylethylenediamine metabolites Half Life: 7-14 hours

FDA Pharmacological Classification · 6 Einträge

81485Y3A9A

GATIFLOXACIN ANHYDROUS

Established Pharmacologic Class [EPC] - Quinolone Antimicrobial

Chemical Structure [CS] - Quinolones

Gatifloxacin anhydrous is a Quinolone Antimicrobial.

Zugehörige Reaktionen

29
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 30450
HRID 30450als Produktuspto-grants-2008_09
Reaktionsgleichung von HRID 202585
HRID 202585als Produktals EduktTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
Reaktionsgleichung von HRID 254868
HRID 254868als Produktuspto-grants-2011_01
Reaktionsgleichung von HRID 311817
HRID 311817als ProduktTraining data from https://doi.org/10.1039/C8SC04228D (8/10)
Reaktionsgleichung von HRID 358862
HRID 358862als Eduktuspto-grants-1991_03
Reaktionsgleichung von HRID 492107
HRID 492107als Produktuspto-grants-2009_05
Reaktionsgleichung von HRID 492108
HRID 492108als Produktuspto-grants-2009_05
Reaktionsgleichung von HRID 492109
HRID 492109als Produktuspto-grants-2009_05
Seite 1 von 4

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Weitere Aktionen
Neue NotizNeue ReaktionAnfrage stellen
ChEBI
CHEBI:5280
UNII
81485Y3A9A
EC Number
664-293-2
Nikkaji
J523.172H

Physikochemische Eigenschaften

Schmelzpunkt
162 °C · 162°C
Siedepunkt
607.8 · 607.8±55.0 °C(Predicted)
Dichte
1.386 · 1.386±0.06 g/cm3(Predicted)
storage temp.
2 · Sealed in dry,2-8°C
Löslichkeit
Chloroform (Slightly, Heated), Methanol (Slightly, Heated)
pka
6.43 · 6.43±0.50(Predicted)
Aggregatzustand
White to yellow crystalline powder.
Farbe
White to Off-White
Major Application
pharmaceutical (small molecule)
InChI
InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
InChIKey
XUBOMFCQGDBHNK-UHFFFAOYSA-N
SMILES
N1(C2CC2)C2=C(C=C(F)C(N3CCNC(C)C3)=C2OC)C(=O)C(C(O)=O)=C1
CAS Datenbank
112811 · 112811-59-3(CAS DataBase Reference)
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 1
hs_code
29335990
risk_code
20/21/22
hazard_code
Xn
safety_code
36/37
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 Oral

GATIFLOXACIN

MeSH Pharmacological Classification · 3 Einträge

Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.

Substances that inhibit the growth or reproduction of BACTERIA.

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.

Absorption, Distribution and ExcretionWell absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%
Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg) in USA (2002): 7250

For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes

Anwendungen · 1 Eintrag

BeschreibungGatifloxacin belongs to a class of drugs known as quinolone antibiotics and is used to treat acute sinus, lung, or urinary tract infections and sexually transmitted bacterial infection.This drug may be taken orally, in tablet form, or by injection.Common side effects associated with gatifloxacin include nausea, vaginitis(irritation or inflammation of the vagina),diarrhea, headache, dizziness, and irregular heart beats. In general, gatifloxacin is used in people who are unresponsive to other AOM therapies.In one study, gatifloxacin was compared with amoxicillin/clavulanate in the treatment of recurrent otitis media (OM) and AOM in treatment failures in children.Three hundred fifty-four infants and children with recurrent OM or AOM failure received gatifloxacin or amoxicillin/clavulanate.Results showed that both drugs were well tolerated; the most common side effect was diarrhea.Researchers concluded that treatment with gatifloxacin once daily was as effective as amoxicillin/clavulanate twice daily.In other medical literature, gatifloxacin has been noted as a third-line treatment option in AOM.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

2,4,5-Trifluoro-3-methoxybenzoic acid

Nachgelagerte Produkte

Gatifloxacin hydrochloride
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an anti iotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.